Jacobson Pharma Corporation Limited (HK:2633)
:2633
Top Page
Jacobson Pharma Corporation Limited
(2633)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$1.50
â–²(16.28% Upside)
Action:ReiteratedDate:10/29/25
Jacobson Pharma Corporation Limited has a strong financial foundation with solid profitability and effective cash management. The valuation is attractive with a reasonable P/E ratio and a high dividend yield. However, technical indicators suggest mixed market momentum, which could pose short-term challenges. The absence of recent earnings call data and corporate events limits further insights.
Positive Factors
Strong operating cash flow
Consistently strong operating cash flow and growing free cash flow provide durable internal funding for R&D, manufacturing and dividends. This cash generation reduces reliance on external financing, supports reinvestment in product development and bolsters resilience across industry cycles.
Negative Factors
Recent revenue contraction
A near-term decline in revenue signals potential demand weakness or portfolio mix headwinds. If persistent, revenue contraction can limit scale benefits, constrain funding for new product launches and slow market share gains; addressing product pipeline or channel reach is key for recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong operating cash flow
Consistently strong operating cash flow and growing free cash flow provide durable internal funding for R&D, manufacturing and dividends. This cash generation reduces reliance on external financing, supports reinvestment in product development and bolsters resilience across industry cycles.
Read all positive factors
Jacobson Pharma Corporation Limited (2633) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.38B
Dividend Yield15.4%
Average Volume (3M)821.71K
Price to Earnings (P/E)5.1
Beta (1Y)0.08
Revenue Growth-1.88%
EPS Growth17.57%
CountryHK
Employees1,730
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,000,221,000
10 Day Avg. Volume1,775,382
30 Day Avg. Volume821,706
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.96
Price to Sales (P/S)1.49
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)HK$1.65B
Jacobson Pharma Corporation Limited Business Overview & Revenue Model
Company Description
Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for var...
How the Company Makes Money
Jacobson Pharma Corporation Limited makes money primarily by selling pharmaceutical and healthcare products through Hong Kong’s healthcare supply chain. Key revenue streams typically include: (1) Sales of prescription pharmaceuticals (branded and/...
Jacobson Pharma Corporation Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
70
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.53B | 1.58B | 1.47B | 1.79B | 1.60B | 1.45B |
| Gross Profit | 679.27M | 692.94M | 620.48M | 747.17M | 620.52M | 534.15M |
| EBITDA | 551.15M | 558.87M | 475.11M | 462.04M | 415.49M | 377.20M |
| Net Income | 302.58M | 300.83M | 266.97M | 251.04M | 177.67M | 173.71M |
Balance Sheet | ||||||
| Total Assets | 3.53B | 3.65B | 3.49B | 5.38B | 4.76B | 4.87B |
| Cash, Cash Equivalents and Short-Term Investments | 395.06M | 509.05M | 411.94M | 1.04B | 478.65M | 480.35M |
| Total Debt | 904.62M | 773.21M | 749.38M | 1.60B | 1.41B | 1.65B |
| Total Liabilities | 1.27B | 1.17B | 1.09B | 2.12B | 1.80B | 2.01B |
| Stockholders Equity | 2.23B | 2.45B | 2.37B | 2.74B | 2.49B | 2.39B |
Cash Flow | ||||||
| Free Cash Flow | 269.04M | 278.39M | 354.85M | 585.23M | 345.89M | 347.99M |
| Operating Cash Flow | 495.89M | 526.78M | 484.36M | 648.24M | 409.76M | 411.35M |
| Investing Cash Flow | -371.63M | -297.76M | 43.34M | -44.09M | -52.75M | -375.40M |
| Financing Cash Flow | -245.49M | -131.30M | -1.05B | -45.64M | -357.89M | 21.36M |
Jacobson Pharma Corporation Limited Technical Analysis
Neutral
1.29
Price Trends
1.25
Negative
1.28
Negative
1.36
Negative
Market Momentum
>-0.01
Negative
53.51
Neutral
82.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2633, the sentiment is Neutral. The current price of 1.29 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.25, and below the 200-day MA of 1.36, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 82.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2633.
Jacobson Pharma Corporation Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.72B | 8.85 | 20.05% | 15.97% | -2.70% | 2.19% | |
75 Outperform | HK$2.18B | 5.29 | 20.10% | 9.98% | 12.83% | 36.12% | |
73 Outperform | HK$7.37B | 6.31 | 10.84% | 5.80% | -20.64% | -25.39% | |
69 Neutral | HK$2.38B | 5.13 | 12.97% | 15.40% | -1.88% | 17.57% | |
66 Neutral | HK$1.74B | 7.90 | 5.33% | 5.16% | 2.89% | -68.83% | |
64 Neutral | HK$712.49M | 6.31 | 5.44% | 2.92% | 19.80% | 55.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2633
Jacobson Pharma Corporation Limited
1.25
0.27
27.55%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.21
0.00
0.00%
HK:2161
JBM (Healthcare) Ltd.
2.65
1.23
86.62%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.16
0.14
13.73%
HK:2877
China Shineway Pharmaceutical Group Limited
9.76
2.90
42.27%
HK:6896
Golden Throat Holdings Group Co Ltd
3.68
0.15
4.25%
Jacobson Pharma Corporation Limited Corporate Events
Jacobson Pharma Awards HK$607 Million Tai Po Facility Infrastructure Contract
Apr 1, 2026
Jacobson Pharma has accepted a HK$607.2 million tender for special infrastructure development and specialised facilities works at its Tai Po Factory, to be carried out by an independent main contractor selected via open tender. The project, funded...
Jacobson Pharma and JBM Renew Connected-Party Framework Deals to 2029
Mar 6, 2026
Jacobson Pharma and JBM (Healthcare) have renewed a set of framework agreements governing their continuing connected transactions, putting in place new 2026 Framework Agreements that will run for three years from 1 April 2026 to 31 March 2029. Amo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.